Navigation Links
MannKind Corporation Reports Second Quarter Financial Results
Date:8/11/2008

, regulatory submissions, manufacturing facility and product demand, that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of clinical trials, difficulties or delays in seeking or obtaining regulatory approval, the manufacture of the Technosphere Insulin System, competition from other pharmaceutical or biotechnology companies, MannKind's ability to enter into any collaborations or strategic partnerships, intellectual property matters and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2007 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

(Tables to follow)

MannKind Corporation

Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share amounts)

Three Months Ended Six Months Ended

June 30, June 30, June 30, June 30,


'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
2. MannKind to Present at Upcoming Conferences
3. MannKind Corporation Reports First Quarter Financial Results
4. MannKind to Present at the Morgan Stanley Healthcare Conference
5. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
6. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
7. MannKind Corporation Response to Recent Market Events
8. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
9. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
10. MannKind to Present at the Wachovia 2008 Healthcare Conference
11. MannKind to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Controlled Substance Compliance Services ... helps companies check the legal requirements around using controlled ... China. , As their international operations expand and ... software solutions built as a result of the first ...
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:12/25/2014)... 25, 2014 The report “Service Quality ... Type & Provider Type - Global Advancements, Worldwide Forecasts ... an in-depth analysis and forecasting of revenues. , ... 221 pages and in-depth TOC on “Service Quality Management ...
(Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   BioLife Solutions ... manufacturer and marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" or ... Annual Meeting of Stockholders on May 4, 2015 (the "Annual ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... Conference Call Today at 8:30 a.m. EST, SOUTH SAN ... ) today reported financial results for,the three and nine months ... 2008, Rigel reported a net loss of $37.7,million, or $1.03 ... or,$0.61 per share, in the third quarter of 2007. Weighted ...
... Calif., Oct. 31 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... minimally invasive treatment of venous reflux disease, today,announced the ... Clinical,Research and Chief Medical Officer., Dr. Smeets joins ... joining VNUS, Dr. Smeets served as the Head of ...
... Oct. 31 SleepQuest has always,followed the essence of ... from,undiagnosed and unexplained health problems related to lack of ... the,importance of identifying and treating sleep disorders. Sleep is ... a wellness factor.,Studies done by the National Commission on ...
Cached Biology Technology:Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 2Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 3Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 4Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 5Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 6VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer 2SleepQuest Tireless in Pursuit of Good Sleep 2
(Date:1/22/2015)... 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is ... the State of Washington,s Department of ... enrollment and central issuance system for driver,s licenses and identification ... project planning and development will start in January 2015, with ...
(Date:1/22/2015)...  Today, FreeWavz ( www.FreeWavz.com ), the developer of ... Fundable, https://www.fundable.com/freewavz . FreeWavz will be expanding ... meet customer demand. Logo - ... Invented by Dr. Eric ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... recent book chapter about sugar-based chemicals is topping ... list. "Sugar-Based Chemicals for Environmentally Sustainable Applications" ... http://pubs.acs.org/doi/abs/10.1021/bk-2010-1061.ch001 and is racking up kudos. ... and research professors A. J. East and W. ...
... treatment processes, in which micro-organisms convert organic matter into ... energy source for heating or electricity. The result is ... the wastewater discharge from polluting industries: pulp and paper, ... with emerging regulations regarding water and waste recycling. ...
... of Florida review of research finds the polyphenol compound known ... may not prevent old age, but it might make it ... a cure for various diseases and a preventative against aging. ... a pill, but it doesn,t exist. But what does exist ...
Cached Biology News:Sugar-based chemicals book chapter by NJIT professor takes ACS kudos 2Water for future generations 2Water for future generations 3UF review of resveratrol studies confirms potential health boost 2UF review of resveratrol studies confirms potential health boost 3
... An immuncapture enzyme-activity assay based on measurenment ... on monoclonal antibody coated microtiter plate. The ... standards, samples or controls, 2nd enzyme ... assay is intended for the determination of ...
... Incubator/Shaker HT is designed for ... Incubator/Shaker HT is ideal for ... and primer extension assays. The ... as a one-cabinet model, allowing ...
... Source: Pseudomonas atlantica Description: Beta-Agarase ... RNA fragments from low-melting-temperature agarose. Beta-Agarase ... disaccharides. Tested User Friendly Properties: Heat ... 30,000 Da Optimum pH: 6.5 Purity: ...
iEMS Thermal Microplate Holder...
Biology Products: